ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over ...

ESSA Pharma (NASDAQ:EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer ...

The new therapy combines two existing cancer drugs, enzalutamide and talazoparib. Enzalutamide, known by its brand name XTANDI, has been used as a treatment for metastatic castration-resistant ...

In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic ...

ESSA Pharma (NASDAQ:EPIX), a biotechnology company focused on developing treatments for metastatic castration-resistant ...

ATTENTION ESSA Pharma Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights ...

The decision to halt the trial, which was assessing masofaniten in combination with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC ...

NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are ...

The 22nd Annual Winter Lung Cancer Conference® will explore advances in neoadjuvant/adjuvant therapies. The FDA has approved Obe-cel for R/R B-ALL, and new treatments in SCLC, lurbinectedin and ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting ...

Abiraterone acetate plus prednisone and enzalutamide improve overall survival (OS) and radiological progression-free survival (rPFS) in docetaxel-pretreated patients. Abiraterone acetate plus ...

The trial tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.